Erschienen in:
01.05.2013 | Clinical Study
A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer
verfasst von:
E. Le Rhun, S. Taillibert, F. Zairi, N. Kotecki, P. Devos, A. Mailliez, V. Servent, L. Vanlemmens, P. Vennin, T. Boulanger, M. C. Baranzelli, C. André, G. Marliot, J. L. Cazin, F. Dubois, R. Assaker, J. Bonneterre, M. C. Chamberlain
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 1/2013
Einloggen, um Zugang zu erhalten
Abstract
Approximately 2–5 % of patients with breast cancer (BC) develop leptomeningeal metastasis (LM). 103 consecutive patients with BC were diagnosed with LM and initially treated with intra-CSF liposomal cytarabine from 2007 to 2011 at a single institution. Correlations were determined with respect to patient characteristics and BC subtype with regard to overall survival (OS). At LM diagnosis, 61 % of patients had a 0–2 performance status (PS), the remaining 39 % were severely neurologically impaired. Regardless of PS, all patients received intra-cerebrospinal fluid (CSF) liposomal cytarabine as first-line treatment. Systemic treatment and radiotherapy were also given in 58 and 17 % of patients respectively as clinically appropriate. Second- (intra-CSF thiotepa) and third-line (intra-CSF methotrexate) treatment was administered in 24 and 6 patients respectively. Median OS was 3.8 months (range 1 day–2.8 years). In multivariate analysis, an initial combined treatment, a second-line treatment with intra-CSF thiotepa, an initial clinical response, and a non-‘ER/PR/HER2 negative’ BC were significantly associated with a better OS. Median OS in this heterogeneous retrospective case series was similar to that of previously observed BC patients treated with intra-CSF methotrexate suggesting intra-CSF liposomal cytarabine is a reasonable first choice therapy of BC-related LM.